Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 11-17 , January 2008

Dopamine D2 receptor radiotracers [11C](+)-PHNO and [3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo

  • Patrick N. McCormick

      Affiliations

    • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada M5S 1A8
    • Corresponding Author InformationCorresponding author. Tel.: +1 416 535 8501x4852; fax: +1 416 979 4656.
    • ,
  • Shitij Kapur

      Affiliations

    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5S 1A8
    • PET Center, Center for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    • ,
  • Philip Seeman

      Affiliations

    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5S 1A8
    • Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8
    • ,
  • Alan A. Wilson

      Affiliations

    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5S 1A8
    • PET Center, Center for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8

Received 7 March 2007 ,Revised 17 August 2007 ,Accepted 17 August 2007.

References 

  1. Sibley DR, De Lean A, Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem. 1982;257(11):6351–6361
  2. George SR, et al. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology. 1985;117(2):690–697
  3. Seeman P, et al. Psychosis pathways converge via D2High dopamine receptors. Synapse. 2006;60(4):319–346
  4. Hwang DR, Kegeles LS, Laruelle M. (−)-N-[(11)C]Propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol. 2000;27(6):533–539
  5. Seneca N, et al. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse. 2006;59(5):260–269
  6. Wilson AA, et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem. 2005;48(12):4153–4160
  7. Ginovart N, et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem. 2006;97(4):1089–1103
  8. Galineau L, et al. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse. 2006;60(2):172–183
  9. Ginovart N, et al. Positron emission tomography quantification of [(11)C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab. 2007;27:857–871
  10. Willeit M, et al. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry. 2006;59(5):389–394
  11. Hwang DR, Narendran R, Laruelle M. Positron-labeled dopamine agonists for probing the high-affinity states of dopamine subtype 2 receptors. Bioconjug Chem. 2005;16:27–31
  12. Narendran R, et al. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (−)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse. 2004;52(3):188–208
  13. Narendran R, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse. 2006;60(7):485–495
  14. Wilson AA, DaSilva JN, Houle S. In vivo evaluation of [11C]- and [18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nucl Med Biol. 1996;23(2):141–146
  15. Ginovart N, et al. Quantitative validation of an intracerebral β-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats. Synapse. 2004;52:89–99
  16. Seeman P, Tallerico T, Ko F. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse. 2003;49(4):209–215
  17. Kapur S, et al. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305(2):625–631
  18. Natesan S, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006;31(9):1854–1863
  19. Andersen PH. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol. 1988;146(1):113–120
  20. McCormick PN, et al. Isoflurane increases both the specific binding ratio and sensitivity to amphetamine challenge of [11C]-(+)-PHNO. Neuroimage. 2006;31:T33
  21. Cumming P, et al. Specific binding of [11C]-raclopride and N-[3H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab. 2002;22:596–604
  22. Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol Pharmacol. 1983;23(2):295–302
  23. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci. 1997;18(12):456–464
  24. Köhler C, Karlsson-Boethius G. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain. J Neural Transm. 1988;73:87–100
  25. Ross SB, Jackson DM. Kinetic properties of the in vivo accumulation of 3H-(−)-N-n-propylnorapomorphine in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1989;340:13–20
  26. Ross SB, Jackson DM. Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1989;340:6–12
  27. Seeman P, et al. Dopamine receptors labelled by PHNO. Synapse. 1993;14(4):254–262
  28. Stemp G, et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem. 2000;43(9):1878–1885
  29. Reavill C, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther. 2000;294(3):1154–1165
  30. Landwehrmeyer B, Mengod G, Palacios JM. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci. 1993;5(2):145–153

PII: S0969-8051(07)00222-3

doi: 10.1016/j.nucmedbio.2007.08.005

Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 11-17 , January 2008

Article Tools

* Image Usage & Resolution